Get All Access for $5/mo

[Funding Alert] Biopharma Start-Up Bugworks Raises $7.5 Mln In Fresh Financing Founded in 2014, the company has been trying to design a completely new class of broad spectrum antibiotics that would be able to fight against increasingly drug resistant bacteria.

Opinions expressed by Entrepreneur contributors are their own.

You're reading Entrepreneur India, an international franchise of Entrepreneur Media.

Bugworks

Biopharma start-up Bugworks Research has raised $7.5 million in a fresh round of funding led by Japan's University of Tokyo Edge Capital and Global Brain Corporation. Acquipharma Holdings of South Africa also participated in the round.

Founded in 2014, the company has been trying to design a completely new class of broad spectrum antibiotics that would be able to fight against increasingly drug resistant bacteria.

The company has so far raised $19 million in funding and counts Siddarth and Pranav Pai-led 3one4 Capital among its early investors. "We have completed all our early-stage work and are moving to an important inflection – clinical trials, which if successful, would then require us to raise another round of funds or find a global partner," co-founder and chief executive officer Anand Anandkumar told Entrepreneur India.

Antimicrobial Resistance

According to the World Health Organization, an additional $1.2 trillion would be required in health expenditure per year by 2050 due to increasing antimicrobial resistance (AMR). In a press release earlier this year, the UN agency said that declining private investment and lack of innovation in the development of new antibiotics were undermining efforts to combat drug-resistant infections.

Anandkumar says that after six years of research and development, Bugworks has managed to crack the bacterial superbug and their solution would be able to work against many different types of bacteria from lung pneumonia to kidney infection.

"What's unique about us as a company is that we use a mixture of modeling, simulation and classical pharmaceutical sciences to design a new generation of antibiotics where we are hitting the bacteria at two spots; it's like hitting your enemy on the head and the heart, very hard for the enemy to dodge two bullets," says Anandkumar.

Headquartered in the United States, the entirety of the company's R&D happens in Bengaluru.

In a statement, Yasuhiko Yurimoto, founder-CEO and general partner at Global Brain, said, "As witnessed with COVID-19, infectious diseases are threatening human existence. AMR is a serious issue and Global Brain regards this as a big unmet medical need. We are proud to partner with Bugworks to bring highly differentiated solutions in AMR to the market."

Need For More

Anandkumar also feels that not enough is being done in the field across the world, something that could potentially lead to extremely drug resistant bacteria. And while they possibly wouldn't spread as fast as a virus, the mortality rates would be much higher.

"Step back for a moment and imagine: no new antibiotics in over 30 years, existing ones are failing, number of hospitals are rising quietly as we speak in our backyard, and it's gonna be like a tsunami, by the time it falls to the shore, it is too late. If you then tell the world to create antibiotics, it's too late because it takes 10-15 years to develop a drug."

He believes that there needs to be a lot more patient capital in the space, as a lot of research might not eventually lead to results, and even for those that do, there needs to be a period of at least 7-10 years for any substantial outcome.

"Our ecosystem has changed very positively, different departments are giving grants, we have multiple incubators across the country; all that is great but the biggest problem is we do not have capital," he says.

Going Forward

If the phase one trial is successful, which they would know by early next year, Bugworks would look to partner with global pharmaceutical companies, who can bring in the money and process power to take the assets to the next phase of trials.

"Even if we do a licensing deal, we want to ensure that we keep the India rights with us so that we can accelerate the product for the Indian markets because unmet need is supremely high in India," says Anandkumar.

Debroop Roy

Former Correspondent

Covering the start-up ecosystem in and around Bangalore. Formerly an energy reporter at Reuters. A film, cricket buff who also writes fiction on weekends.
Business Solutions

Right Now, You Can Get More Than 310 Hours of IT Training for Just $50

Stay ahead in tech with the CompTIA Super Bundle.

News and Trends

Fast Fire Watch Guards: Protecting Your Business From Today's Fire Hazards

As a watch guard company, Fast Fire Watch Guards provides vigilant monitoring and immediate responses to signs of potential fire hazards in commercial spaces.

News and Trends

growX Ventures Launches Fund II with a Target Corpus of INR 400 Cr

Fund II aims to target early-stage and growth-stage investments, backing 20–24 startups in deeptech sectors. It plans to deploy INR 10 crore in seed and INR 20–30 crore in Series B rounds.

Business News

Here's What the CPI Report Means for Your Wallet, According to JPMorgan and EY Experts

Most experts agree that there will be another rate cut next week.

News and Trends

Recur Club Announces Credit Offerings for Startups Beyond Series A and SMEs

In FY 24–25, the platform also plans to deploy an additional INR 2000 crores through its Recur Swift program for startups.

Business Ideas

63 Small Business Ideas to Start in 2024

We put together a list of the best, most profitable small business ideas for entrepreneurs to pursue in 2024.